Vertex stock falls after pain drug VX-993 fails Phase 2 trial, despite better-than-expected Q2 earnings and strong cystic fibrosis drug sales.
Latest Ratings for VRTX
DateFirmActionFromTo Feb 2022RBC CapitalDowngradesOutperformSector Perform Jan 2022BMO CapitalUpgradesMarket PerformOutperform Dec 2021Wells FargoInitiates Coverage OnOverweight